Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis
Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. - Background - Non-insulin-dependent diabetes mellitus dialysis patients have the highest cardiovascular mortality known in any group of patients. Mixed dyslipidemia with moderately elevated low-density lipoprotei...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
1 July 1999
|
| In: |
Kidney international
Year: 1999, Volume: 56, Pages: S222-S226 |
| ISSN: | 1523-1755 |
| DOI: | 10.1046/j.1523-1755.1999.07158.x |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1046/j.1523-1755.1999.07158.x Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0085253815466463 
|
| Author Notes: | Christoph Wanner, Vera Krane, Günther Ruf, Winfried März, and Eberhard Ritz |
| Summary: | Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. - Background - Non-insulin-dependent diabetes mellitus dialysis patients have the highest cardiovascular mortality known in any group of patients. Mixed dyslipidemia with moderately elevated low-density lipoprotein (LDL) cholesterol and high levels of triglyceride-rich lipoproteins is common in this condition. It is not known, however, whether patients with type 2 diabetes on dialysis with this form of dyslipidemia derive benefit from lipid-lowering therapy. Recently, drugs have become available that potently lower triglyceride-rich, apoB-containing lipoproteins and thus permit testing of this issue. This is the first trial to address specifically the issue of whether the excessive cardiovascular mortality of patients with type 2 diabetes on dialysis can be lowered by statins. |
|---|---|
| Item Description: | Gesehen am 28.10.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1523-1755 |
| DOI: | 10.1046/j.1523-1755.1999.07158.x |